Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
Stopped early · Phase 1
Conditions studied: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
In brief
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme \[CYP\]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on the study drug, vesatolimod (VES), in people with HIV-1 on antiretroviral therapy (ART).
Key facts
- Study ID
- NCT05458102
- Run by
- Gilead Sciences
- People needed
- 18
- Starts
- 2022-08-19
- Expected to finish
- 2023-05-01
- Last updated by the study team
- 2024-12-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Collaborative Neuroscience Research, LLC. — Long Beach, California, United States
- Clinical Pharmacology of Miami, LLC. — Miami, Florida, United States
- Advanced Pharma, CR, LLC. — Miami, Florida, United States
- Triple O Research Institute, P.A. — West Palm Beach, Florida, United States
- Hassman Research Institute — Marlton, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.